Its additional ability to interact with Cldn5 is of advantage for potential NSCLC treatment, since NSCLC is characterized by upregulation of several claudins including both Cldn1 and Cldn5 (Paschoud et al., 2007). Here, CLDN5 is linked to non-small cell lung carcinoma.